Letter:
We thank Chen and Yan for their thoughtful and positive comments on our recent publication and for their interest in the translational implications of SMPDL3B biology in myalgic encephalomyelitis (ME) [1, 2]. Their letter provides a welcome opportunity to clarify methodological points related to biomarker validation, in vitro pharmacological assays, and mechanistic interpretation [3]. We appreciate this constructive dialogue and address each issue below in a collegial and scientifically grounded manner.
Read the rest of this letter HERE>>
Source: Rostami-Afshari B, Elremaly W, Franco A, Moreau A. Authors’ Response to “Comment on ‘SMPDL3B as a novel biomarker and therapeutic target in myalgic encephalomyelitis'”. J Transl Med. 2026 Jan 16;24(1):75. doi: 10.1186/s12967-025-07583-z. PMID: 41546078; PMCID: PMC12809929. https://pmc.ncbi.nlm.nih.gov/articles/PMC12809929/ (Full text)